hrcak mascot   Srce   HID

Prethodno priopćenje
https://doi.org/10.2478/acph-2021-0013

Sitagliptin: a potential drug for the treatment of COVID-19?

SANAA K. BARDAWEEL   ORCID icon orcid.org/0000-0002-4823-0708 ; Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan
RIMA HAJJO ; Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733 Jordan
A. DIMA A. SABBAH ; Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733 Jordan

Puni tekst: engleski, pdf (1 MB) str. 175-184 preuzimanja: 44* citiraj
APA 6th Edition
BARDAWEEL, S.K., HAJJO, R. i SABBAH, A.D.A. (2021). Sitagliptin: a potential drug for the treatment of COVID-19?. Acta Pharmaceutica, 71 (2), 175-184. https://doi.org/10.2478/acph-2021-0013
MLA 8th Edition
BARDAWEEL, SANAA K., et al. "Sitagliptin: a potential drug for the treatment of COVID-19?." Acta Pharmaceutica, vol. 71, br. 2, 2021, str. 175-184. https://doi.org/10.2478/acph-2021-0013. Citirano 02.12.2020.
Chicago 17th Edition
BARDAWEEL, SANAA K., RIMA HAJJO i A. DIMA A. SABBAH. "Sitagliptin: a potential drug for the treatment of COVID-19?." Acta Pharmaceutica 71, br. 2 (2021): 175-184. https://doi.org/10.2478/acph-2021-0013
Harvard
BARDAWEEL, S.K., HAJJO, R., i SABBAH, A.D.A. (2021). 'Sitagliptin: a potential drug for the treatment of COVID-19?', Acta Pharmaceutica, 71(2), str. 175-184. https://doi.org/10.2478/acph-2021-0013
Vancouver
BARDAWEEL SK, HAJJO R, SABBAH ADA. Sitagliptin: a potential drug for the treatment of COVID-19?. Acta Pharm. [Internet]. 2021 [pristupljeno 02.12.2020.];71(2):175-184. https://doi.org/10.2478/acph-2021-0013
IEEE
S.K. BARDAWEEL, R. HAJJO i A.D.A. SABBAH, "Sitagliptin: a potential drug for the treatment of COVID-19?", Acta Pharmaceutica, vol.71, br. 2, str. 175-184, 2021. [Online]. https://doi.org/10.2478/acph-2021-0013

Sažetak
Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical literature for high confidence DPP4-protein/gene associations followed by functional analysis using network analysis and pathway enrichment was adopted. The results indicate that the identified DPP4 networks are highly enriched in viral processes required for viral entry and infection, and as a result, we propose DPP4 as an important putative target for the treatment of COVID-19. Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. We conclude that sitagliptin may be beneficial for the treatment of COVID-19 disease, either as monotherapy or in combination with other therapies, especially for diabetic patients and patients with pre-existing cardiovascular conditions who are already at higher risk of COVID-19 mortality.

Ključne riječi
SARS-CoV-2; COVID-19; DPP4; ACE2; sitagliptin; drug repurposing; XCL10

Hrčak ID: 237515

URI
https://hrcak.srce.hr/237515

Posjeta: 119 *